The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a protease inhibitor (PI)-based regimen to an efavirenz-based regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels < 50 copies/mL. In addition, a simplified once-daily regimen will improve adherence and quality of life.

Two plasma HIV RNA levels < 50 copies/mL during the qualification and screening period

Patients receiving a PI and ≥ 2 NRTIs

Exclusion Criteria:

Pregnancy or breastfeeding

Documented virologic failure while on their first PI-based antiretroviral (ARV) regimen

Active AIDS-defining opportunistic infection or disease

Proven or suspected acute hepatitis within 30 days prior to study entry

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00135382